Good Thank you, afternoon. Jim.
non-XX one the hours Hetlioz Sleep-Wake since identified than Disorders. XX,XXX non-XX time, Rhythms This we have Circadian the than Disorder. four more of more launch this various years have quarter At for of marks who patients
non-XX revenue XX% Our Hetlioz commercialize quarter. year-over-year innovative approach to achieving to growth drive growth a continues this significant
building continue the investigations order study top-line [indiscernible] to of have Syndrome, the Drug SMS, results in supplemental have and New into disorder. on delayed At Sleep-Wake same the Disorder. have we We our completed initiating to enrollment now FDA end In a to are market Application and submitted Smith-Magenis success now by the year. we time, plan of
people. the Sleep Disorders for One of more population the of than X.X% effecting a common Circadian Rhythm about most million
Now on Fanapt, two initiating programs. with a significant through are XXXX, conviction on Fanapt clinical the exclusivity two of we
designing in episodes and mixed soon bipolar beginning announce in maniac are will We next disorder and the year. currently study
and will milestone treated study in formulation affecting a the clinical iloperidone We need Tradipitant gastroparesis. the in we indications the and in of initiated significant alone. Phase our formulation about month our to for around up is for for pharmacokinetic exciting is U.S. efficacy year. most next Vanda people psychotic once have of and also - weeks II few injectable and medical with this come can once six commercial first disorder of studies month The Tradipitant. it coming injectable common Gastroparesis further results the poorly a a unmet the a of the top-line from disorder million development believe formulation proposed that the opportunities of bipolar next significantly planned our increase begin asset. studies We
ability week Tradipitant four four outcomes twice over with of drug evaluate gastroparesis weeks. weeks a of day to which report Our symptoms results XX of be the II reported of patient XXX is is by next study four double blind blind we Tradipitant patient placebo will month endpoint improvement by design two to in daily primary of includes double nausea system study a the of the the measured screening, Phase The arm, of improve The period. diaries. period a of will followed milligram
than for of mechanism to Our is in today around agent of as the commonly from [indiscernible], limited for gastric safety stems the efficacy of improve receptors however as in vomiting symptoms areas efficacy things. concerns. the action summer used NKX are hypothesized its is of brain in and gastroparesis most nausea Tradipitant prescribed and conviction suggesting two NKX being [indiscernible] receptors which responsible gastroparesis every is More possible acne. XXX,XXX targeting for dual patients significant months The well
seeking First, patients that of second large patients number even of an a unfigured. and are large and treatment receiving remain
II report study this is program. currently On atopic of to atopic in our Phase of the recruiting label III Tradipitant working the EPIONE, expect on in design in year. study of dermatitis efficacy meantime, Phase the results Briefly we open December patient of the sometime large patients. III studies XXX Phase are the In We dermatitis.
We expected have completion to to study, efficient we understand the improve not as ways continue recruitment. most of the the communicated
excited our and additional CFPR early program. our be A development assets Trichostatin to in our pursuing program continue the we in While pipeline including
of launch will are revenue in four our year-over-year financial results, growth accomplishment highlight specifically want the We I a of visualization market. to and our focused for the month. in and excited in of XX% expectations assets the the gastroparesis detail and programs the Jim but SMS review achieving important years since of next the results U.S. repeat our receptions
website. of to a want reported - our We relating briefly the recently corporate matter. received regulatory from letter I Finally, warning to a FDA address page the
conclusion the turn with While will removed are resolve to financial agency's results. third discuss question in the seeking quarter we temporarily material have the either this to we and Jim our the agency's do that With over issue we the action I agree call to or agency. not with now
